Structural basis for the activity of drugs that inhibit phosphodiesterases - Wikidata - wikimedia - TriplyDB

Structural basis for the activity of drugs that inhibit phosphodiesterases

Structural basis for the activity of drugs that inhibit phosphodiesterases

http://www.wikidata.org/entity/Q28296195

about

Cyclic nucleotide specific phosphodiesterases of Leishmania major.Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)PDE4 inhibitors: current status Structural insight into substrate specificity of phosphodiesterase 10 Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies Solution Structure of the cGMP Binding GAF Domain from Phosphodiesterase 5: INSIGHTS INTO NUCLEOTIDE SPECIFICITY, DIMERIZATION, AND cGMP-DEPENDENT CONFORMATIONAL CHANGE Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the γ-subunit Discovery of Novel Trypanosoma brucei Phosphodiesterase B1 Inhibitors by Virtual Screening against the Unliganded TbrPDEB1 Crystal Structure Fragment-Based Screening for Inhibitors of PDE4A Using Enthalpy Arrays and X-ray Crystallography Structural basis for the design of selective phosphodiesterase 4B inhibitors RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5 PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum Ultrafast protein structure-based virtual screening with Panther.Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.Evolution of multiple phosphodiesterase isoforms in stickleback involved in cAMP signal transduction pathway An automated stochastic approach to the identification of the protein specificity determinants and functional subfamilies.Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors A fission yeast-based platform for phosphodiesterase inhibitor HTSs and analyses of phosphodiesterase activity.Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors Advances in targeting cyclic nucleotide phosphodiesterases Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold.Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4 Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A.Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.Domain organization and conformational plasticity of the G protein effector, PDE6.Structure-based design of selective phosphodiesterase 4B inhibitors based on ginger phenolic compounds.Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient.Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.2-(5,6-Diphenyl-1,2,4-triazin-3-yl)aniline.Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase Evaluation of PDE4 inhibition for COPD.Treating COPD with PDE 4 inhibitors.

P2860

Q21093362-F246D394-EB4B-43AE-AAC0-A8432A1BDA39 Q24569706-AD2043D4-26C1-42D0-9D1D-D394D5FC6F28 Q24634179-AA9A1C31-9652-41E6-B7D2-19AB5A796428 Q24651926-FAA75E10-242B-4E22-B749-271C2083191F Q27644254-C56DA56B-2E51-4594-BB65-B0CEF503612F Q27648887-D0218AEC-D4BD-4929-8485-245DC5A38914 Q27650091-D4BB125A-899B-42CB-A5D8-B42FA391FE11 Q27650760-91CD994B-A1FD-482E-A077-F8E4A2373FCF Q27657633-14465AA3-8E1C-4300-A64F-18C47788ABC2 Q27676380-3937B233-1B45-423D-B139-211814AB6A90 Q27676592-FD56681F-3097-4947-9401-383E548F4C0E Q27681021-566A1C37-D779-45D8-B1D9-145C4CAADFD0 Q28386161-5BD9370D-9D42-4F38-B487-312190A8C4C0 Q30045366-AB6CC323-942E-4ED4-B141-5687244861D9 Q30379556-7A066B0C-5A03-499C-9F9D-5ADABF9D7D27 Q30381467-3F62F405-C788-47EE-B467-F5353C6862FA Q31145317-B419F685-9A07-472E-BE67-1F49645B5A87 Q33243131-88BF02FE-7954-4ECB-9857-82EF4CA8CEF2 Q33341310-0660E958-DB0D-48AF-BF4F-AD6A0F1DC25D Q33411044-1F8B2CBB-2380-4330-9350-29FE026A5AC0 Q33633470-ACDED488-8882-4210-9E38-6B541C63BC36 Q33853315-DEAE9023-4281-469A-9011-210BD44DEC28 Q33939889-BD31B763-970D-42CB-9E93-D49B4CE9F9B2 Q34138086-6B32CF1C-F8FC-48FC-90A6-0514257F5824 Q34139490-B95E727E-D5C6-46EA-9FEF-144015403C80 Q34420467-7F4D71F7-C2A5-4FC5-90BA-D11A5DBF24EB Q34984650-468C56E2-73C9-429F-9D00-A89A858BFD09 Q35065003-566315F7-3066-4AAC-9118-5E08E07B9E35 Q35229437-F3BAD1C3-2317-4F7C-A540-F846B2074ED8 Q35535258-415484D2-5A0F-4B6E-89AA-1A20D3916D50 Q35544406-4E733CDB-0B74-4D14-A5BA-8C9E702E2F36 Q35587147-F6C27664-6803-49C3-BE2A-3E25A4BD6B5F Q35608151-D3480D50-5008-445F-83C5-2C1E97D74087 Q36127167-16167BC7-9958-4951-AC81-8CD0B43E18EF Q36350472-14A417ED-5B19-40B6-A3F1-B361953206D4 Q36436130-57DD7116-0EDE-44D2-B899-6390971EA872 Q36658226-924ACC3A-D997-45AA-972A-7F50D0705054 Q36855547-F082612F-807F-46B2-8B36-D8E77D48566E Q37017332-1A2F83E1-F108-43EC-A7AC-3CCA960C389D Q37082594-AA862AD1-7564-4DC8-9A97-860D6296E6ED

P2860

Structural basis for the activity of drugs that inhibit phosphodiesterases

http://www.wikidata.org/entity/Q28296195

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Structural basis for the activity of drugs that inhibit phosphodiesterases

@ast

Structural basis for the activity of drugs that inhibit phosphodiesterases

@en

Structural basis for the activity of drugs that inhibit phosphodiesterases

@nl

type

label

Structural basis for the activity of drugs that inhibit phosphodiesterases

@ast

Structural basis for the activity of drugs that inhibit phosphodiesterases

@en

Structural basis for the activity of drugs that inhibit phosphodiesterases

@nl

prefLabel

Structural basis for the activity of drugs that inhibit phosphodiesterases

@ast

Structural basis for the activity of drugs that inhibit phosphodiesterases

@en

Structural basis for the activity of drugs that inhibit phosphodiesterases

@nl

P1433

Q28296195-014E7775-0AF0-4B3D-8E4B-1606817C7983

P1476

Q28296195-291A1A78-25FF-4C22-B0F4-49510A870478

P2093

Q28296195-01C82C92-28EC-48F6-9404-CB130C78D695

Q28296195-0C7D2987-9188-4327-8942-0DEA9FF8B01E

Q28296195-121A6C05-D8BC-4C4B-BA30-65F1C1686F27

Q28296195-200F6394-64A2-4025-B2BE-AE0B4732B048

Q28296195-224622CE-F2A4-4859-959B-17ADC7771A86

Q28296195-3D33194B-6C6D-46AB-B28C-115106EC9EAE

Q28296195-3E1A989E-3775-48EC-8E12-25984C66AFF0

Q28296195-7387242E-EEAD-469F-8181-A36F6B164653

Q28296195-A2D45FD5-ECBF-46DF-AFF3-6343E9198E7E

Q28296195-B18A123E-0ED7-44C8-AFDC-7ADB74C3A42C

P304

Q28296195-B08962B7-01B4-4690-88D0-D26376A7CD72

P31

Q28296195-65E909A2-2AC6-463B-8770-4E01D1A80617

P356

Q28296195-550A33AC-D000-4315-8BC9-9952870F2AE4

P407

Q28296195-75DE57E4-D384-4E21-8A9E-7064D15E4229

P433

Q28296195-77D97113-6D12-4769-BFE2-9546B1CBD243

P478

Q28296195-F782E8F8-847A-4368-8EA2-F567A8359349

P50

Q28296195-52AEED3D-0E20-4BFC-854B-2F98091631B1

Q28296195-84F886AC-95C0-4B09-916D-02BFABE6A6BB

Q28296195-A29EE404-32E4-4638-B59F-9AA0D045F169

P577

Q28296195-5E7FAF23-7679-479C-B62F-F39FB18F105A

P5875

Q28296195-3C4CF3C2-7B07-4D37-83F8-A218B50AB216

P698

Q28296195-68823D84-80F8-41F0-A79A-5B3E82214D40

P356

J.STR.2004.10.004

P1433

P1476

Structural basis for the activity of drugs that inhibit phosphodiesterases

@en

P2093

Ben Powell

http://www.w3.org/2001/XMLSchema#string

Bruce P England

http://www.w3.org/2001/XMLSchema#string

Byunghun Lee

http://www.w3.org/2001/XMLSchema#string

Catherine Luu

http://www.w3.org/2001/XMLSchema#string

Daniel Fong

http://www.w3.org/2001/XMLSchema#string

Dean R Artis

http://www.w3.org/2001/XMLSchema#string

Graeme L Card

http://www.w3.org/2001/XMLSchema#string

Kam Y J Zhang

http://www.w3.org/2001/XMLSchema#string

Maryam Tabrizizad

http://www.w3.org/2001/XMLSchema#string

Michael V Milburn

http://www.w3.org/2001/XMLSchema#string

P304

2233-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.STR.2004.10.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Joseph Schlessinger

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8151717

http://www.w3.org/2001/XMLSchema#string

P698

15576036

http://www.w3.org/2001/XMLSchema#string